ProfileGDS5678 / 1432598_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.988833
GSM967853U87-EV human glioblastoma xenograft - Control 21.97023
GSM967854U87-EV human glioblastoma xenograft - Control 31.97263
GSM967855U87-EV human glioblastoma xenograft - Control 41.922693
GSM967856U87-EV human glioblastoma xenograft - Control 51.91983
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.015013
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.9763
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.947493
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.941393
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.960443
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.953533
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.946413
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.961673
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.960063